Affiliation:
1. State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center
2. The Seventh Affiliated Hospital of Sun Yat-sen University, China
Abstract
Abstract
Background
The Chinese Liver Cancer (CNLC) staging recommends transarterial chemoembolization (TACE) as the standard treatment for hepatocellular carcinoma (HCC) patients with macrovascular invasion and without extrahepatic metastasis (CNLC IIIa). As a recently emerging approach, the efficacy of hepatic arterial infusion chemotherapy (HAIC) compared to TACE in this group of patients is unclear.
Methods
From December 2016 to June 2020, patients diagnosed with CNLC IIIa stage HCC who underwent TACE (n = 91) or HAIC (n = 190) as their initial treatment were included. Propensity score matching (PSM) was used to reduce selection bias and other imbalances. Objective response rates (ORR), overall survival (OS), progression-free survival (PFS), rate of subsequent resection, and safety were compared in these two groups.
Results
After PSM, 77 pairs of patients were matched. The ORR was higher in HAIC group than that of TACE group (29.9% vs. 9.1%, P = 0.013). Median progression-free survival of the HAIC group was longer than that of TACE group (4.7 vs. 1.4 months, P = 0.002), but there was no significant difference in the median OS between the HAIC and TACE groups (19.6 vs. 18.1 months, P = 0.122). The HAIC group also showed a better safety profile than the TACE group.
Conclusions
HAIC is an effective and safe option in the treatment of HCC patients with CNLC IIIa stage compared with TACE.
Publisher
Research Square Platform LLC
Reference25 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;Ca-a Cancer Journal for Clinicians,2021
2. Cancer statistics in China, 2015;Chen W;CA Cancer J Clin,2016
3. Hepatocellular carcinoma;Forner A;Lancet,2018
4. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Benson AB;J Natl Compr Canc Netw,2021
5. N.H.C.o.t.P.s.R.o.C., [Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)];Bureau of Medical Administration;Zhonghua Gan Zang Bing Za Zhi,2022